Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abliva’s NV354 receives ODD from US FDA
Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial
Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial
The multi-year strategic partnership will leverage latest molecular profiling approaches guiding patient selection and participation to accelerate precision medicine approaches across five of the therapeutic programmes of Flare.
The definitive agreement between the companies was initially signed in January this year. The total deal value at close is nearly $1.2bn in upfront consideration and contingent value
Co-led by global investors Insight Partners and M Ventures, the financing round has also seen participation from Gaingels and One Way Ventures. ImmuneBridge is developing allogeneic NK cell-based
The receipt of the drug distribution licence by Hainan Asieris is an important step towards improving drug circulation services, standardising management, and promoting drug imports and distribution in
Located at the TÜBITAK MAM Gebze campus in Kocaeli province close to Istanbul, the MEDIBIYO facility can generate biotechnological drugs and vaccines that align with good manufacturing practice
With regard to the closure of the deal, AcelRx got a total of around $2.7m from Aguettant and Alora. Alora agreed to acquire all assets associated to DSUVIA
It also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The firm raised the amount from Syncona Investment Management, and Cambridge Innovation Capital. Proceeds
The gene therapy is used for the treatment of inherited retinal disease (IRDs) caused by RPE65 mutations. Retina is impacted in patients who suffer from RPE65 mutation-associated IRDs and
Entresto (sacubitril/valsartan) is intended for treating symptomatic chronic heart failure with left ventricular systolic dysfunction in patients who are aged from 1 to <18 years. Novartis global head